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Abstract
Background: MicroRNAs (miRNAs) are short, non-coding RNAs that regulate the expression of multiple target genes.
Deregulation of miRNAs is common in human tumorigenesis. Low level expression of miR-26b has been found in glioma
cells. However, its underlying mechanism of action has not been determined.
Methodology/Principal Findings: Real-time PCR was employed to measure the expression level of miR-26b in glioma
patients and cells. The level of miR-26b was inversely correlated with the grade of glioma. Ectopic expression of miR-26b
inhibited the proliferation, migration and invasion of human glioma cells. A binding site for miR-26b was identified in the
39UTR of EphA2. Over-expression of miR-26b in glioma cells repressed the endogenous level of EphA2 protein. Vasculogenic
mimicry (VM) experiments were performed to further confirm the effects of miR-26b on the regulation of EphA2, and the
results showed that miR-26b inhibited the VM processes which regulated by EphA2.
Significance: This study demonstrated that miR-26b may act as a tumor suppressor in glioma and it directly regulates EphA2
expression. EphA2 is a direct target of miR-26b, and the down-regulation of EphA2 mediated by miR-26b is dependent on
the binding of miR-26b to a specific response element of microRNA in the 39UTR region of EphA2 mRNA.
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Introduction
MicroRNAs (miRNAs) are short single stranded RNA mole-
cules, which serve as master regulators of gene expression.
miRNAs regulate gene expression in a sequence-specific fashion;
miRNAs bind to 39untranslated regions (UTRs) of mRNAs and
then affect the translation and/or stability of that mRNA, leading
to a reduction in protein levels. Tumors analyzed by miRNA
profiling have exhibited significantly distinct miRNA signatures
compared to normal cells from the same tissue [1,2]. The
abnormal levels of miRNAs in tumors have important pathoge-
netic consequences [3]. Some miRNAs are over-expressed in
tumors and act as oncogenes, promoting tumor aggravation by
down-regulating tumor suppressors [4]. For example, the miR-17-
miR-92 cluster in T-cell acute lymphoblastic leukemia reduces the
level of the transcription factor E2F1 [5,6]; miR-21 down-
regulates the tumor-inhibiting factor PTEN in lung cancer cells;
and miR-125b is an important repressor of p53 and inhibits p53-
induced apoptosis in human neuroblastoma cells [7]. On the other
hand, tumors lost miRNAs generally participate in oncogene over-
expression. For example, the let-7 family represses Ras and Myc
oncogenes in cancers [8,9], and the miR-15-miR-16-1 cluster
down-regulates Bcl-2 and induces apoptosis in a leukemic cell line
model [10].
miR-26b is one of the miRNAs involving in the response to
hypoxia, a well documented tumor microenvironment factor [11].
Recent study confirmed that the expression of miR-26b was
changed in several human cancer cell lines including glioma cells,
[12]. miRNA profile analyses revealed that miR-26b was one of
the significantly decreased miRNAs in glioma cells compared to
normal brain tissues [12]. However, the role of miR-26b in glioma
development has not been well documented and little is known
about its target genes. Additionally, the effect of abnormal
expression of miR-26b on tumor grade needs to be addressed.
Erythropoietin-producing hepatocellular (EPH) receptors and
their Ephrin ligands constitute the largest sub-family of receptor
tyrosine kinases (RTKs), which are involved in many biological
processes and play important roles in disease and development
[13]. To date, 14 Eph receptors have been found in mammals.
They were divided into two distinct classes, A and B, based on the
sequence homology of their extracellular domains. More recently,
EphA receptors and their corresponding ligands have been
implicated in numerous malignancies [14]. Among them, EphA2
and ephrinA1 are the most widely studied with respect to
development, tumorigenesis, angiogenesis, and metastasis and
they may represent as the potential therapeutic targets because of
their diverse functions in several types of cancer. Studies have
shown that activation of the EphA2 receptor tyrosine kinase by
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16264ephrinA1 ligands played important roles in cellular signal
transduction. [15]. EphA2 is implicated and functionally altered
in a number of cancers and has potential roles in the regulation of
cancer cell growth, survival, migration, invasion, and angiogenesis
[16,17,18]. Increased expression of EphA2 has been demonstrated
in most cancers of epithelial origin, like breast [19], ovarian
[17,20], prostate [21], melanoma [22], esophageal [23,24,25],
lung carcinomas [26] and brain [27,28]. Immunohistochemical
analysis has revealed that EphA2 was strongly over-expressed in
90% of GBM patient tumors [27], 85% of prostate adenocarci-
nomas and 76% of ovarian cancers [18]. Furthermore, the
frequent over-expression of EphA2 in human cancers correlates
with poor prognosis and increases metastatic potential [18]. In
epithelial cells, ectopic expression of EphA2 has been shown to
result in a malignant phenotype in both in vitro and in vivo
experiments [19]. EphA2 has been proposed as an attractive target
for developing novel anticancer therapeutic agents.
In this study, the expression of miR-26b in glioma cells and the
tissues from glioma patients with certain grades was studied by
real-time PCR analysis. Proliferation, migration, and invasion
were analyzed to confirm the effects of miR-26b in glioma cells.
The regulation of miR-26b on EphA2 was confirmed by the
experiments of luciferase analysis, Western blotting, and Vascu-
logenic mimicry (VM) network formation. We found that ectopic
expression of miR-26b in U251 and C6 glioma cells resulted in
diminished proliferation, migration and invasion activity, accom-
panied by a low level expression of EhpA2. VM formation was also
abolished in glioma cells transfected with the miR-26b duplex.
Our study provides evidence that miR-26b acts as an anti-
oncogene in glioma cells and is an important negative regulator of
the EphA2 gene.
Results
The expression of miR-26b in tissues of glioma patients has not
been well documented. In order to determine the relationship
between miR-26b expression and glioma grades, the expression of
miR-26b in normal brain tissues, glioma tumors and glioma cell
lines was analyzed by real-time stem-loop RT-PCR. The results
showed that in normal brain tissues, miR-26b exhibited a relative
high level expression, whereas the expression of miR-26b was
significantly (p,0.01) down-regulated in glioma samples (WHO I,
WHO II, WHO III and WHO IV). The expression of miR-26b
becomes lower with increasing grades of glioma. The expression of
miR-26b was also down-regulated in the three tested glioma cell
lines, U251, U87 MG and C6 (Fig. 1).
We next determined the effect of miR-26b on the proliferation of
glioma cells. The growth ability of glioma cells was determined by
MTT assay. As shown in Fig. 2A, over-expression of miR-26b
resulted in the growth inhibition of both U251 human glioma cells
and C6 rat glioma cells. However, the growth inhibition induced by
miR-26bwas abolished whenanantisenseofmiR-26b(26b-AS)was
introduced into the cells (Fig. 2A). In contrast, substituting the 26b-
AS with a negative control single strand RNA (NC-AS), similar
inhibition effect on cell proliferation was found as the transfected
26b-DP alone (Fig. 2A). We examined the inhibitory effect of miR-
26b on glioma cells at different time points and found that the
maximum inhibition was at the 48 h (Fig. 2B). The inhibition rates
were 34.28% and 29.547% in U251 and C6 cells transfected with
26b-DP, respectively (Fig. 2B). These results suggest that miR-26b
plays a key role in the proliferation of some glioma cells, and might
function as a tumor suppressor in glioma cell lines.
To evaluate the role of miR-26b in glioma cell migration, a
wound healing assay was performed. An artificial wound was made
24 h after transfection with 26b-DP, and the cells migrating into the
wound were measured after culturing for another 24 h. As shown in
Fig. 3A, the migration was significantly decreased in U251 and C6
cells transfected with 26-DP (Fig. 3A). To determine the invasion
ability of glioma cells, an in vitro Matrigel invasion assay was
employed. As shown in Fig. 3B, cell invasion was markedly reduced
in the cells transfected with 26b-DP, exhibiting a 67.98% and
51.78% in reduction of invasion with a statistically significant
Figure 1. The expression of miR-26b in glioma samples and U251, U87 MG and C6 cells. The grade of glioma was evaluated according to
WHO criteria as described in Materials and Methods. Samples ID 1–5 are from normal brain tissues; ID 6–10 from pilocytic astrocytomas classified to
WHO I: ID 11–15 from astrocytoma classified to WHO II; ID 16–20 from anaplastic astrocytomas classified to WHO III; and ID 21–25 from Glioblastoma
Multiforme classified to WHO IV. Each sample was divided by a dashed line. Total RNA was isolated from the glioma tissues and glioma cells of U251,
U87 MG and C6 and real-time PCR was performed to analyze the expression of miR-26b as described in Materials and Methods. The relative
expression of miR-26b was expressed as the ratio of the expression level of U6. **P,0.01, as compared to Normal brain tissues group.
doi:10.1371/journal.pone.0016264.g001
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The results suggest that over-expression of miR-26b inhibits the
ability of invasion and migration of glioma cells.
We then tried to find the target genes of miR-26b using the
online miRNA target prediction programs miRanda (http://www.
microrna.org), TargetScan (http://www. targetscan.org) and
PicTar (http://www.pictar.bio.nyu.edu). Approximately 100 tar-
gets of miR-26b were predicted from these programs. EphA2 was
of particular interest because previous studies revealed that its
expression level was enhanced in approximately 90% of GBM
specimens [27,28]. Therefore, we assumed that the decreased
expression of miR-26b resulted in the high level of EphA2. Here we
detected the expression of EphA2 in normal brain, glioma samples
of different grades, and three glioma cell lines. Indeed, we found
that expression of EphA2 was significantly enhanced with the
advance of glioma grade(p,0.01), accompanying the decrease of
miR-26b (Fig. 4A). Moreover, the results predicted by TargetScan
5.1, miRBase Target and PicTar showed that there was a specific
target site of miR-26b on 39UTR of EphA2 (Fig. 4C) and miR-26b
was one of the conserved miRNAs targeting EphA2 in both human
and murine (Fig. 4D). The putative miRNA response elements
(MREs) of miR-26b were also found in the 39UTRs of EphA2 in
other vertebrates when compared across distant species (data not
shown). These results suggest that miR-26b is likely to be an
important regulator of EphA2.
We confirmed the binding of miR-26b to the 39UTR of human
EphA2 using a luciferase reporter assay (Fig. 5A). Ectopic
expression of miR-26b significantly suppressed the luciferase
activity in HEK-293 cells co-transfected with miR-26b duplex
(26b-DP) and Luc+miR-26b MRE, which contained the miR-26b
response element (MRE) region in the 39UTR of human EphA2
(Fig. 5B). Similarly, the activity of luciferase in the cells co-
transfected with miR-26b and the construct Luc+wt EPhA2
39UTR, which contains the entire 39UTR region of human
EphA2, was suppressed by 60,70% (P,0.01) (Fig. 5B). In
contrast, suppression of luciferase activity was almost abolished
when the miR-26b MRE was deleted from the 39UTR of EphA2
(Fig. 5B). The inhibition of luciferase activity was also greatly
decreased when introducing a 3-base mismatch mutation into the
seed region of the MRE in the 39UTR of EphA2 (Fig. 5A and B).
These data indicate that the predicted MRE is critical for the
direct and specific binding of miR-26b to EphA2 mRNA.
To study the regulation of endogenous EphA2 by miR-26b, 26b-
DP was transfected into U251 and C6 cells, both of which express
high levels of EphA2.A nEphA2 specific siRNA [29] was transfected
as a positive control. When the EphA2 siRNAs were transfected into
U251 or C6cells, the expression levelof endogenous EphA2 proteins
was inhibited nearly 90% (Fig. 5C and D). Ectopic expression of
miR-26b in U251 cells reduced the level of EphA2 protein by ,60%
(p,0.01) (Fig. 5C and D). The expression of EphA2 protein was
reduced ,70% in C6 cells transfected with miR-26b (Fig. 5C and
D). These results indicate that miR-26b is a regulator of Eph2A in
glioma cells, and that the miRNA can down-regulate the expression
of EphA2 at the protein level.
In order to further confirm the function of miR-26b as an EphA2
regulator, we next studied the effect of miR-26b in U87 MG
glioma cells expressing only low levels of endogenetic EphA 2 [27]
(Fig. 4B). Compared to U251 and C6 which expressed high levels
of EphA2 (Fig. 4A and B), the cell proliferation reduced by miR-
26b were not significant (p.0.05) in the U87 MG cells (Fig. 6A).
The growth ability of glioma cells in U87 MG, U251, and C6 cells
transfected with 26b-DP was reduced with inhibition rates of
10.11% (Fig. 6A), 34.28% and 29.54% (Fig. 2B), respectively,
suggesting that the inhibition rates of 26b-DP transfectants were
related to endogenous EphA2 levels in glioma cells. Similarly, the
reduction of migration activity in U87 MG cells transfected with
26b-DP was also not notable (Fig. 6B) compared with that in U251
and C6 glioma cells (Fig. 3A). Additionally, as shown in Fig. 3B
and 3C, transfection with 26b–DP greatly reduced the ability of
U251 and C6 cells to invade Matrigel, exhibiting about 67.98%
and 51.78% in reduction of invasion, respectively. However, in
U87 MG, only 11.73% reduction was found compared with the
cells transfected with scrambled oligonucleotides (NC-DP) (Fig. 6C
and D). These results provide solid evidence that miR-26b
suppresses glioma cell proliferation, migration and invasion
activity in a manner dependent on EphA2 expression level.
Glioma is an extremely invasive, well-vascularized tumor. It has
been reported that vasculogenic mimicry (VM) exists in glioma
[30] and EphA2 is an important regulator for VM formation. In
order to evaluate the effects of miR-26b and EphA2 on VM
Figure 2. Ectopic expression of miR-26b inhibits glioma cell
proliferation in vitro. (A) The proliferation of glioma cell lines, U251
and C6. Cells were first transfected with miR-26b duplex, negative
control RNA duplex, co-transfected with 26b-DP and miR-26b specific
antisense oligonucleotides (26b-AS) or negative antisense oligonucle-
otides (NC-AS). After incubation for 48 h, cell proliferation rates were
analyzed by MTT assay. The growth rates of cells transfected with NC-
DP were defined as 1.0. **P,0.01, as compared to NC-DP group. (B) The
cell proliferation inhibition rates of glioma cell lines of U251 and C6
after miR-26b transfection at certain time points. 26b-DP was
transfected into U251 or C6 cells, and the cell proliferation inhibition
rates were evaluated by MTT assay at 12, 24, 36, 48 and 72 h. The
inhibitory rates of cells were the percentage of the ratio of cells
proliferation transfected with miR-26b to that transfected with NC-DP.
doi:10.1371/journal.pone.0016264.g002
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experiments in U87 MG, U251 and C6 cells. As shown in Fig. 7A,
U251 and C6 glioma cells, which expressed high levels of EphA2,
could develop VM networks when cultured in Matrigel for 24 h
(Fig. 7 I and III) and the VM network showed a positive reaction
with periodic acid-Shiff (PAS) (Fig. 7 II and IV). In contrast, VM
network was not found in U87 MG cells which expressed low level
of EphA2 (data not shown). Our primary finding suggested that
VM network formation was dependent, at least in part, on the
expression of EphA2. Therefore, we transfected the miR-26b
duplex (26b-DP) into glioma cells to determine if down-regulation
of EphA2 could affect the VM formation. As predicted, our results
showed that the VM network could not be formed in either U251
or C6 cells (Fig. 7 V and VII). However, we did find that over-
expression of EphA2 fully rescued from the effects of miR-26b
when a EphA2 expression vector lacking the 39UTR (pCMV6-
XL6-EphA2) was delivered into the miR-26b over-expressed
U251 and U6 cells (Fig. 7 VI and VIII). These results suggested
that EphA2 plays a key role in the VM formation, and miR-26b
affects the VM formation by down-regulation of EphA2 expression
in glioma cells.
Discussion
In the present report we detected the miR-26b expression level
in human glioma samples and found that the decreased expression
Figure 3. Effect of miR-26b over-expression on glioma cell migration and invasion. (A) Wound healing assay was employed to evaluate
the effects of miR-26b on glioma cell migration as described in Materials and Methods. U251 and C6 cells were transfected with 26b-DP or NC-DP at a
final concentration of 50 nM/L. When the cell confluence reached about 90% at 48 h post-transfection, an artificial homogenous wound was made as
described in Materials and Methods. The boundary of the wound was marked by two solid lines. The experiments were preformed in triplicate and
the representative images of photographs at 0 h and 24 h post-wounding are shown at 1006magnification. (B) Effect of miR-26b over-expression on
glioma cells invasion. Glioma cells transfected with 26b-DP or NC-DP were plated on Matrigel-coated membranes in the upper chamber of transwells.
After incubation for 24 h, non-invading cells on the upper surface of the membrane were removed and the invasive cells on the lower surface were
stained with 0.1% Crystal Violet. The stained invasive cells were photographed under an inverted light microscope (1006 magnifications).
(C) Quantitative results of glioma cell invasion. Invasive cells were quantified by manual counting and the number represents the mean of six
counting sights 6 SEM. The experiments were performed in triplicate with three independent experiments. Statistically significant differences
between the groups of 26b-DP and NC-DP were observed: **P,0.01.
doi:10.1371/journal.pone.0016264.g003
miRNA-26b Targets EphA2 in Glioma
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e16264level of miR-26b was negatively correlated with the increased
malignancy of glioma. Transfection of miR-26b duplex decreased
the aggressive feature of glioma cells, suggesting that miR-26b
plays a critical role in glioma development, and it may act as an
anti-tumor factor in glioma cells.
Our studies indicate that EphA2 is a novel target gene of miR-
26b, and the direct interaction between miR-26b and EphA2
mRNA is supported by several lines of evidence: (1) the 39UTR of
both human and murine EphA2 mRNAs contain a putative
binding site (the MRE) for miR-26b with significant seed match;
(2) miR-26b suppresses the activity of a luciferase reporter fused
with the 39UTR of EphA2 mRNA in an MRE dependent manner;
(3) miR-26b represses the endogenous expression of human/
murine EphA2 at both the mRNA and protein level; (4) A previous
study has shown that EphA2 gene knockdown by siRNAs resulted
in failure of VM formation [29]. Similar results were found in our
present study, when miR-26b was over-expressed in U251 and C6
cells, the VM process was impaired, suggesting that miR-26b
affects VM formation of glioma cells by down-regulating EphA2.
This study is the first to identify a miRNA that directly regulates
EphA2.
EphA2 expression is frequently elevated in cancers and is
associated with poor prognosis [17–19,24,31]. High levels of
EphA2 have been reported in diverse cell lines and clinical
specimens, including breast, colon, prostate, non-small cell lung
cancers, aggressive melanomas and glioblastoma [14,18]. Howev-
er, EphA2 does not appear to function simply only as a biomarker
[27] but also actively participated in malignant progression
[17,20,28]. For example, ectopic expression of EphA2 in non-
transformed mammary epithelial cells is sufficient to promote a
malignant phenotype as defined using in vitro and in vivo methods
[19]. It has been reported that knockdown of EphA2 in cancer cells
Figure 4. EphA2 is a predicted target of miR-26b. (A) The mRNA expression level of EphA2 in glioma samples and glioma cell lines. The mRNA
expression level of EphA2 was detected by real-time PCR. The grades of glioma were classified in Materials and Methods. The experiments were
preformed more then three times. The relative expression of EphA2 was the ratio of the expression level of to that of b-actin. **P,0.01, as compared
to Normal brain tissues group. (B) The protein expression level of EphA2 in U251, U87 MG and C6 cells. Western blotting analysis was performed to
evaluate the expression level of EphA2 in different glioma cells. b-actin was used as a loading control. (C) The shaded region represents the MRE
sequences of miR-26b in the 39UTR of human EphA2 mRNA as predicted by TargetScan 5.1, miRBase and Pictar. (D) The predicted miR-26b binding
site in EphA2 39UTR is highly conserved in mammals. The miR-26b seed sequences and their predicted binding sites in the EphA2 39UTR are shown
underlined.
doi:10.1371/journal.pone.0016264.g004
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we showed that high level expression of EphA2 was found in high
grade glioma samples. Our study is consistent with other studies
that high level expression of EphA2 plays a critical role in cell
malignancy. Additionally, we further confirmed that miR-26b is
an important regulator of EphA2, and there was an interaction
between miR-26b and EphA2 in glioma cells. The inhibition
induced by miR-26b in glioma cells is partly dependent on the
expression of EphA2. This finding increases our understanding of
EphA2 function and regulation in glioma cells.
Vasculogenic mimicry (VM) was first described in highly
aggressive uveal melanomas which formed vasculogenic networks
with tumor cells instead of endothelial cells [33]. VM is associated
with tumor blood supply and tumor metastasis. In recent years, VM
has been seen in several types of malignant tumors such as breast
cancer [34], liver cancer, glioma, ovarian cancer [35], melanoma
[33], prostate cancer [36], colorectal cancer [37] and some other
bidirectional differentiated malignant tumors [38]. It has been
reported that VM also exists in glioma cells [30]; high aggressive
glioma cells can form VM in three dimension culture medium [39].
EphA2 is known to be an important regulator during VM formation
[14,29,38,40]. Knockdown of EphA2 in malignant melanoma cells
impaired formation of the VM network [29]. EphA2 expression was
found in both highly aggressive uveal and cutaneous melanoma
cells, but not in poorly aggressive melanoma cells. Moreover, down-
regulation of EphA2 expression using a specific small interference
RNA (siRNA) inhibits VM formation in aggressive melanoma cells
[40]. In the present work, U251 and C6 glioma cells, which express
Figure 5. miR-26b binds to the 39UTR of EphA2 mRNAs. (A) Synthesis of luciferase reporter assay constructs for validating the interaction of
miR-26b with the 39UTR of EphA2. ‘‘S’’ in the Shaded region indicates the ‘‘seed’’ regions in the 26b-MRE of the 39UTR of EphA2 mRNAs. The predicted
MRE or the whole EphA2 39UTR was inserted into a psiCheck2 vector immediately downstream of the Renilla luciferase gene to construct the
luciferase reporter vectors, Luc+miR-26b MRE and Luc+wt EphA2 39UTR, respectively. Luc+MRE deleted 39UTR was also constructed with a similar
approach. A mutation in the seed region of miR-26b MRE of EphA2 39 UTR was made using the Quick change sit-Directed mutagenesis kit to construct
the Luc+MRE mutated 39UTR vector. (B) Quantitative analysis of luciferase activity. HEK-293T cells were transfected with NC-DP, 26-DP, co-transfected
with 26b-DP and 26b-AS or NC-AS. After incubation for 48 h, luciferase activity was analyzed as described in Materials and Methods. The activity of
Renilla luciferase was normalized to that of the control firefly luciferase in each experiment. The luciferase activity in cells transfected with control
miRNA (NC-DP) was defined as 100%. The values represent the Mean 6 SEM (n$6) from at least three independent experiments. The two-tail t-Test
was employed to statistically analyze the results. (**) P,0.01 vs. NC-DP transfected controls. (C) Over-expression of miR-26b down-regulates EphA2
expression in U251 and C6 cells. Various miRNAs were transfected into U251 or C6 cells and the level of EphA2 was analyzed by Western blotting as
described in Materials and Methods. (D) Quantitative results of EphA2 expression. Quantitation of signal intensities was performed using
densitometry on a Hewlett-Packard ScanJet 5370 C. The percentage of EphA2 expression represents the ratio of EphA2 to b-actin expression (n$3).
The relative expression level of EphA2 siRNA treated group was used as a positive control. The two-tail t-test was employed to statistically analyze the
results: ** P,0.01.
doi:10.1371/journal.pone.0016264.g005
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contrast, the VM networks could not be formed in U87 MG cells,
which have low levels of EphA2. The result further suggests that
EphA2 plays a critical role in VM formation in glioma cells. We
further demonstated that the function of EphA2 is regulated by miR-
26b; transfection of miR-26b duplex into U251 and C6 cells
inhibited their ability to form VM networks. However, when we
transfected these cells with EphA2 expression vector without the
39UTR regain, the VM destroyed by over-expression of miR-26b
were fully restored. The formation of vasculogenic like networks has
not been well understood; the processes involve several signaling
molecules, including vascular endothelial (VE)-cadherin, erythro-
poietin-producing hepatocellular carcinoma-A2 (EphA2), phospha-
tidylinositol 3-kinase, focal adhesion kinase, matrix metalloprotei-
nases and laminin 5 c2-chain [38]. Here we found that miR-26bis a
negative regulator of EphA2 in VM formation. This finding provides
insight into the function of miRNAs and EphA2 in regulating VM
processes.
In conclusion, this study demonstrates that miR-26b plays a key
role in the malignancy of glioma cells by directly regulating EphA2
expression, which affects cell proliferation, migration and invasion.
VM formation was also affected by ectopic expression of miR-26b.
This study helps us to better understand of the function of miR-
26b and its regulation of EphA2 in glioma cells. However, further
study is needed to determine if EphA2 activity is affected by miR-
26b in other cancers with high EphA2 expression, like breast
cancer, colon cancer, and prostate cancer; and whether miR-26b-
EphA2 dysregulation represents a new mechanism for cellular
transformation.
Materials and Methods
Cell lines and tumor tissues
Human HEK-293T cells, human glioma U251 and U87 MG
cells and rat glioma C6 cells were purchased from the American
Type Culture Collection (ATCC, MD). All cell lines were
Figure 6. Effects of miR-26b on proliferation, migration and invasion in U87 MG cells. (A) Effect of miR-26b over-expression on U87 MG
cell proliferation. U87 MG cells were first transfected with miR-26b duplex, negative control RNA duplex (NC-26DP), co-transfected with 26b-DP and
miR-26b specific antisense oligonucleotides (26b-AS), or negative antisense oligonucleotides (NC-AS). Then, the cell proliferation rates were analyzed
by MTT assay after 48 h incubation. The growth rates of cells transfected with NC-DP were defined as 1.0. There was no significant difference (P.0.05)
among all tested groups. (B) Effect of miR-26b over-expression on migration in U87 MG cells. U87 MG cells were transfected with 26b-DP or NC-DP at
a final concentration of 50 nM/L. When the cell confluence reached about 90% at 48 h post-transfection, an artificial homogenous wound was made
as described in Materials and Methods. The boundary of the wound was marked by two solid lines. The experiments were preformed in triplicate and
the representative images of photographs at 0 h and 24 h post-wounding are shown at magnification of 1006. (C) Effect of miR-26b over-expression
on migration and invasion in U87 MG cell. U87 MG cells transfected with 26b-DP or NC-DP were plated on Matrigel-coated membranes in the upper
chamber of transwells. After incubation for 24 h, non-invading cells on the upper surface of the membrane were removed and the invasive cells on
the lower surface were stained with 0.1% Crystal Violet. The stained invasive cells were photographed under an inverted light microscope (1006
magnifications). (D) Quantitative results of glioma cell invasion. Invasive cells were quantified by manual counting and the number represents the
mean of six counting sights 6 SEM. The experiments were performed in triplicate with three independent experiments.
doi:10.1371/journal.pone.0016264.g006
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supplemented with 10% fetal bovine serum (Invitrogen, CA) and
1% penicillin-streptomycin (Invitrogen, CA). Cells were routinely
passaged at 2 to 3 day intervals.
Tissue samples from human glioma and normal brain tissues
were obtained from the Brain Institute, Qingdao Medical
University Associate Hospital (Qingdao, China). Samples were
collected and stored at 280uC. The histopathologic diagnoses
were determined using WHO criteria and evaluated by the
hospital’s pathologist using both morphologic criteria and
immunocytochemistry. Written consent of tissue donation for
research purposes was obtained from the patients before tissue
collection and the protocol was approved by the Institutional
Review Board of the Affiliated Hospital of Qingdao Medical
University. Twenty-five samples were used for this study with 5
samples for each group, including primary grade pilocytic
astrocytomas (WHO I), grade II astrocytoma (WHO II),
grade III anaplastic astrocytomas (WHO III), grade IV Glioblas-
toma Multiforme (WHO IV) and normal brain tissues derived
from the temporal lobes and saddle area of the patients with
arachnoid cyst (AC) after surgery. The clinical data and patient
information are shown in Table S1. All samples were thoroughly
reviewed by the neuropathologist Dr. W.C Yao in the Brain
Institute, Affiliated Hospital of Qingdao Medical University
(Qingdao, China).
RNA isolation
Total RNA was extracted from the frozen tissue samples or
cultured cells using the TRIzol kit (Invitrogen, CA) following the
manufacturer’s protocol. Briefly, tissue samples were homogenized
in TRIzol reagent using an Omni-Mixer Homogenizer (Omni
International, CA). The cells were collected from a culture flask
into RNase free tubes, and TRIzol solution (Invitrogen, CA) was
added. RNA quantity was determined by UV measurement of OD
260/280 nm using the NanoDrop 2000 instrument (Thermo
Scientific, FL).
Real-time quantitative RT-PCR
To quantitate the expression level of mature miR-26b
(MIMAT0000083), the isolated RNA was reverse transcribed
and amplified by a two-step quantitative RT-PCR method using
the Hairpin-it TM miRNAs qPCR Quantitation Kit (Gene-
pharma, Shanghai, China) according to the manufacturer’s
protocol. miR-26b specific reverse primers and the sequence-
specific primers for mature miR-26b were designed according to
Chen et al. [41] and their sequences are listed in Table 1. PCR
reactions were performed using an ABI 7300 System (Bio-Rad,
CA) with the following conditions: 95uC, 10 min for 1 cycle, then
95uC, 15 s, 60uC, 1 min for 40 cycles. Signals were detected at the
end of each cycle. The U6 small nuclear RNA was amplified as a
loading control. The primers for this U6 internal control were
provided by Genepharma (Shanghai, China). The relative
expression level of mature miR-26b from each sample was
determined using the 2(2Delta Delta C(T) Method [42].
Real-time PCR for EphA2 was performed using the ABI 7300
System (Bio-Rad, CA) with the QuantiTect SYBR Green PCR
mixture (Invitrogen, CA). b-actin was used as control. Primers used
for detecting gene expression are listed in Table 1. Expression of
EphA2 was determined using the 2(2Delta Delta C (T) Method.
Amplification conditions were as follows: 95uC, 3 min, 95uC, 30 s,
60uC, 30s, 72uC, 40s, for 40 cycles, and 72uC, 8 min for extension.
Transfection
The two miRNA mimics used in the experiments were
purchased from Dharmacon company (Dharmacon, CO), and
the sequence of NC-DP microRNA, as a negative control, is based
on cel-miR-67(MIMAT0000039) and it has been confirmed to
have minimal sequence identity with miRNAs in human, mouse
and rat. Another microRNA mimics is 26b-DP, which is a duplex
of miR-26b. The antisense of two microRNAs, negative antisense
of negative control microRNA, cel-miR-67 (NC-AS) and miR-26b
antisense (26b-AS) were also provided by Dharmacon. Certain
amount of miRNA duplexes (NC-DP and 26b-DP) and antisense
Figure 7. Vasculogenic mimicry (VM) formation assay. U251 cells (I) or C6 cells (III) transfected with negative control microRNA (NC-DP) were
seeded onto 6-well plates. ECM Matrigel was dropped onto 18-mm glass coverlips in 6-well tissue culture plate and incubated at 37uC for 30 min and
then seeded on the coated coverlips. The VM formation was assessed using an inverted microscope after growth for 24 h. II and IV represent the
U251 and C6 network formation stained by PAS, respectively. U251 (V) and C6 (VI) cells were transfected with 26b-DP, the transfected cells were
seeded on the coated coverlips after 24 h incubation. The VM formation was assessed using an inverted microscope after growth for another 24 h.
The U251 and C6 cells tansfected with 26b-DP first, then EphA2 expression vector which not include the 39UTR (pCMV6-AC-GFP-EphA2) was co-
transfected after 24 h incubation, respectively. The VM formation in U251 (VI) and C6 (VIII) cells was assessed using an inverted microscope after
growth for another 24 h.
doi:10.1371/journal.pone.0016264.g007
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MG, U251 or C6 cells, respectively. EphA2 expression vector
(pCMV6-AC-GFP-EphA2) which contains the full length human
EphA2 gene ORF sequence without the 39-UTR region of EphA2
was purchased from OriGene Technologies (OriGene Technolo-
gies, MD). The pCMV6-AC-GFP-EphA2 vector was transfected
into U251 or C6 cells with 20 nm/L. Specific siRNAs targeting
EphA2 (Genepharma, Shanghai, China) were transfected at
100 nm/L. Lipofection 2000 (Invitrogen, CA) was used as the
transfection reagent following the manufacturer’s protocol.
Synthesis of luciferase reporter constructs
To construct the luciferase reporter vectors, the predicted miR-
26b binding site (miRNA response element, MRE) on the EphA2
39UTR or the whole 39UTR of EphA2 were inserted into the XhoI
and NotI sites of a psiCheck2 vector (Promega, WI) immediate
downstream of the Renilla luciferase gene. The sense and
antisense sequences of the MRE were synthesized, annealed,
and ligated into the psiCheck2 vector to construct a miR-26b
MRE luciferase reporter, Luc+miR-26bMRE. The full length 39
UTR of human EphA2 was amplified from the total cDNA of
U251 cells and inserted into TOPO PCR2.1 (Invitrogen, CA) and
then ligated into the psiCheck2 vector to synthesize the luciferase
report constructs Luc+wt EPhA2 39UTR. Another construct,
Luc+MRE deleted 39UTR, in which the miR-26b MRE region of
EphA2 39UTR is deleted was also constructed with a similar
approach. A mutation in the seed region of miR-26b MRE of the
EphA2 39 UTR was made using the Quick change sit-Directed
mutagenesis kit (Stratagene, CA) according to the manufacturer’s
instructions. The construct, Luc+MRE mutated 39UTR, was
synthesized by ligating the mutation fragment into the psiCheck2
vector. The sequences of MRE and all primers are listed in
Table 1.
Luciferase reporter assay
miRNA duplexes, including the negative control duplex (NC-
DP) and miR-26b duplex (26b-DP), and miRNA antisense
oligonucleotide, including the negative control antisense (NC-AS)
and miR-26b antisense (26b-AS) were purchased from Dharma-
con and dissolved in ddH2O. Each luciferase reporter construct,
including Luc+miR-26bMRE, Luc+wt EPhA2 39UTR, Luc+MRE
deleted 39UTR and Luc+MRE mutated 39UTR was co-
transfected with 50 nm/L of miRNA duplexes or 100 nm/L
miRNA antisense into HEK-293T cells in a 24-well plate using
Lipofectamin-2000 (Invitrogen, CA). After incubation for 48 h,
cells were harvested by centrifugation at 1000 g for 10 min and
lysed using lysis buffer. Firefly and Renilla luciferase activities were
determined with the Dual-Luciferase reporter system (Promega,
WI) following the manufacturer’s protocol.
Western blotting analysis
U251 or C6 cells were transfected with Oligonucleotides (26b-
DP or NC-DP, or 26b-AS or EphA2 siRNAs). After incubation for
72 h, the transfected cells were harvested by centrifugation at
1000 g for 10 min and lysed using ice-cold RIPA buffer (50 mM
Tris–HCl, 1% NP40, 0.25% Na-deoxycholine, 150 mM NaCl,
1 mM EDTA). PMSF was added at a final concentration of
1 nm/mL. Protein concentrations were determined using the
BCA protein assay kit (Thermo Scientific, FL). Whole-cell lysates
(50 mg protein) were resolved by 9% SDS-PAGE and electro-
blotted onto nitrocellulose membranes using the Idea electropho-
resis system (Idea scientific, MN). Membranes were incubated in
blocking solution (16 PBS, 0.1% Tween-20, and 5% nonfat dry
milk powder) for 2 h at room temperature, and then incubated for
1 h with primary antibodies at the following dilutions: Rabbit
monoclonal antibodies against human EphA2 with 1:500 dilutions
(H-20, sc-48789, Santa Cruz Biotechnology, CA) or mouse
polyclonal antibody against b-actin diluted 1:1000 (E-5, sc-
47778, Santa Cruz Biotechnology, CA). After washing 10 minutes
with 16 PBS and 0.1% Tween-20 for three times, membranes
were incubated with horseradish peroxidase-conjugated secondary
antibody (IgG goat anti-rabbit or anti-mouse; 1:2000; Bio-Rad,
CA) for 1 h at room temperature. After an additional three
10 minute washes with 0.1% Tween-20 in PBS buffer, the
Table 1. Primer sequences.
Primer name Type Sequence 59 to 39
b-actin -F RT PCR forward primer GTTGCGTTACACCCTTTCTTG
b-actin -R RT PCR reverse primer GTCACCTTCACCGTTCCAGT
EphA2-F RT PCR forward primer CACTTACCGCAAGAAGGGAGA
EphA2-R RT PCR reverse primer ACAGCCACGCCGCCAATCA
miR-26b-RT [41] miR-26b RT primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACCTAT
miR-26b-F [41] RT PCR forward primer CGCCGCTTCAAGTAATTCAGGAT
miR-26b-R [41] RT PCR reverse primer GTGCAGGGTCCGAGGT
EphA2-MRE-F MRE top strand tcgagCATCGGCCAAGAATACTTGAAgc
EphA2-MRE-R MRE bottom strand ggccgcTTCAAGTATTCTTGGCCGATGc
EphA2-UTR-F PCR forward primer CCGctcgagCCTGGAGCCCCATCGGCCAAGAATA
EphA2-UTR-delF MRE delete primer TTCCTTTTgcggccgcCAGAGTGGCCTCCCTGCTGTGCCAT
EphA2-UTR-R PCR reverse primer TTCCTTTTgcggccgcAGAGCAGAAATAAGTCATTTTC
EphA2-UTR 3misF Mutagenesis primer GGAGCCCCATCGGCCAAGAATgtTTcAAGAAACAGAGTGG
EphA2-UTR 3misR Mutagenesis primer CCACTCTGTTTCTTGAAacATTcTTGGCCGATGGGGCTCC
EphA2-siRNAF [29] EphA2 siRNA forward strand CCAGCAGTACCGCTTCCTTGCCCTGCGGCCG
EphA2-siRNAR [29] EphA2 siRNA forward strand GCCGCGTCCCGTTCCTTCACCATGACGACC
Lower case text indicates restriction enzyme sites; Lower case with underline indicates mismatched mutations in miR-26b seed region.
doi:10.1371/journal.pone.0016264.t001
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using Super Signal West Dura (Thermo Scientific, FL) and protein
bands were visualized by autoradiography. Quantitation of signal
intensities was performed using densitometry on a Hewlett-
Packard ScanJet 5370C (Hewlett-Packard, CA) with NIH image
1.62 software.
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bro-121 mide] assay
U251 or C6 cells (5610
3) were plated onto 96-well plates and
allowed to adhere overnight. The cells were transfected with 26b-
DP at the final concentration of 50 nm or 26b-AS at the final
concentration of 100 nm using Lipofectation 2000 reagent
(Invitrogen, CA). At certain time points (12, 24, 36, 48 and
72 h) after transfection, MTT dye (30 mL, 5 mg/ml, Sigma-
Aldrich, MO) was added to the culture medium. After incubation
at 37uC for 4 h, the MTT solution was removed and 150 mL
dimethyl sulfoxide (DMSO, Sigma-Aldrich, MO) was added to
dissolve the formazan crystals. Spectrometric absorbance at
490 nm was measured by Multiskan EX microplate photometer
(Thermo Scientific, FL).
Wound healing assay
Cell culture and transfection conditions were optimized to
ensure a homogeneous and viable cell monolayer prior to
wounding. One day before transfection, U251 (3.5610
5), U87
MG (3.5610
5)o rC 6( 5 610
5) cells were seeded onto 6-well plates.
Cells were then transfected with 50 nm/L 26b-DP or NC-DP
using the Lipofectation 2000 transfection reagent. When the cell
confluence reached about 90%, at 48 h post-transfection, an
artificial homogenous wound was made onto the monolayer with a
sterile plastic 200 mL micropipette tip. After wounding, cell debris
was removed by washing the cells with serum-free medium. After
incubation for another 24 h, the cells that migrated into the
wounded area or with extended protrusion from the border of
wound were photographed using an inverted microscope (406
magnifications) (CKX41, LYLMPAS, Japan).
In vitro invasion assay
U251, U87 MG or C6 cells were plated in 6-well plates and
transfected with final concentration of 50 nm 26b-DP or 100 nm
26b-AS as mentioned above. After incubation for 48 h, the cells
were treated with 0.25% trypsin–EDTA (Hyclone, Japan),
collected by centrifugation at 1000g, and re-suspended into
serum-free medium. Transfected cells (5610
4) were reseeded into
the upper chamber of transwells. 20% FBS was added to the
medium in the lower chamber. After incubation for another 24 h,
non-invading cells on the upper surface of the membrane were
scrubbed gently with a cotton-tipped swab. The invasive cells on
the lower surface of the membrane were fixed with 95% methanol
and stained with 0.1% Crystal Violet (Sigma-Aldrich, MO). The
stained invasive cells were photographed under an inverted light
microscope (1006 magnification) and quantified by manual
counting in three randomly selected areas. The experiments were
performed in triplicate in three independent experiments.
Vasculogenic mimicry formation assay
Vasculogenic mimicry (VM) formation experiments were
performed as previously described [33] with a little modification.
Briefly, 50 mL ECM Matrigel (Sigma-Aldrich, CA) was dropped
onto 18-mm glass coverlips in 6-well tissue culture plates and then
incubated at 37uC for 30 min. U251 and C6 cells (5610
5) were
transfected with 26b-DP, 26b-AS or contransfected with 26b-DP
and EphA2 expression vector (pCMV6-XL6-EphA2) a day before
seeded onto the coated coverlips. After growth for 24 or 48 h on
the coverlips, VM formation was assessed using an inverted
microscope (CKX41, LYLMPAS, Japan). Additionally, the
periodic acid-Shiff’s Reaction (PAS) staining of VM formation
was performed as described by Maniotis et al. [33]. Briefly, cells
cultured on coverlips were fixed with 95% ethanol for 5 min,
oxidized in 0.5% periodic acid solution for 5 min, rinsed using
distilled water 3 times and placed in Schiff reagent for 15 min, and
then the coverslips were immediately picked out and washed with
lukewarm tap water for 5 min. The coverlips were dried at room
temperature and the PAS signal was photographed using an
inverted light microscope at 406magnifications.
Statistics
Statistical analyses were performed using the software from
SPSS for Windows 13.0 (SPSS Inc., IL). All data were described as
mean 6 SEM. To analyze the data statistically, we performed
Student’s t-test for the analysis. Differences were considered
significant when P,0.05.
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